成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 166663-25-8 Chemical Structure| 166663-25-8

Structure of Anidulafungin
CAS No.: 166663-25-8

Chemical Structure| 166663-25-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 166663-25-8

,{[proInfo.pro_purity]}

Anidulafungin is an echinocandin antifungal agent used to treat invasive Aspergillus infection, working by inhibiting (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.

Synonyms: LY303366; VER-002; VEchinocandin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Anidulafungin

CAS No. :166663-25-8
Formula : C58H73N7O17
M.W : 1140.24
SMILES Code : OC1CC(C(NC(C(NC(C(N2C(C(NC(C(CC(C(NC(C3=O)C(C)O)=O)NC(C4=CC=C(C=C4)C5=CC=C(C=C5)C6=CC=C(C=C6)OCCCCC)=O)O)O)=O)C(C(C2)C)O)=O)C(O)C)=O)C(C(C7=CC=C(C=C7)O)O)O)=O)N3C1
Synonyms :
LY303366; VER-002; VEchinocandin
MDL No. :MFCD00917070

Safety of Anidulafungin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319-H361
Precautionary Statements:P264-P270-P301+P312-P330-P501-P305+P351+P338-P337+P313-P280-P201-P202-P281-P308+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
African green monkey kidney cells (Vero) 5, 10, 20 μM 1 hour Evaluate the inhibitory effect of Anidulafungin on SFTSV infection, results showed that Anidulafungin effectively inhibits SFTSV entry into cells. PMC9585728
Candida glabrata 0.01 to 0.1 mg/L 24 h and 48 h To determine the minimum inhibitory concentration (MIC) of Anidulafungin against Candida glabrata. Results showed that MIC values were identical at 24 and 48 hours, and for both 50% and ≥95% reduction in turbidity. PMC1635198
Candida auris 0.016 to 8 mg/L 24 hours Evaluate the in vitro synergistic activity of Anidulafungin in combination with manogepix or 5-flucytosine against Candida auris, showing synergistic effects PMC10269148
Candida auris (South American clade) 0.25, 1, 8, 16, 32 mg/L 24 hours Anidulafungin showed a negligible fungistatic effect against the isolates from Israel but was fungistatic against the environmental isolates. PMC10222763
Candida auris (South African clade) 0.25, 1, 8, 16, 32 mg/L 24 hours Anidulafungin produced a weak fungistatic effect against the South African clade isolates. PMC10222763
Candida auris (East Asian clade) 0.25, 1, 8, 16, 32 mg/L 24 hours Anidulafungin showed concentration-dependent killing activity against the type strain and fungistatic activity against the other isolates. PMC10222763
Candida auris (South Asian clade) 0.25, 1, 8, 16, 32 mg/L 24 hours Anidulafungin exhibited weak fungistatic activity against wild-type isolates and the isolate with a mutation in the hot-spot 2 region of FKS1 but was ineffective against the isolates with a mutation in the hot-spot 1 region. PMC10222763
BV2 microglia cells 1 μM 24 hours To evaluate the protective effect of Anidulafungin against Aβ oligomer-induced cytotoxicity. Results showed 1 μM Anidulafungin significantly attenuated AβO-induced cytotoxicity, restoring cell viability to 93.30% (vs. 68.66% with AβO alone). PMC11342299
Candida auris clinical isolates 0.06-4 μg/mL 48 hours Evaluate the antifungal effect of Anidulafungin in combination with citral, showing synergistic effects against 36.84% of isolates and additive effects against 57.89% PMC10300739

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Caenorhabditis elegans C. elegans infection model Liquid media 0.06 and 0.25 μg/mL Observed every 24 hours for 120 hours Evaluate the in vivo antifungal effect of Anidulafungin in combination with citral, showing significantly increased survival rates of nematodes PMC10300739
CD1 mice Invasive aspergillosis model Intraperitoneal injection 1 and 5 mg/kg/day Initiated 2 h post-infection, continued for 5 days (day 0 to day 4) Assessed therapeutic efficacy of Anidulafungin alone and combined with amphotericin B. AFG (1 and 5 mg/kg/day) and combinations significantly prolonged survival, but combinations were not superior to monotherapy; 5 mg/kg/day reduced kidney fungal burden but was ineffective in brain tissues. PMC2737837
Female outbred Swiss Webster mice Neutropenic model of disseminated candidiasis Intraperitoneal injection 1 to 20 mg/kg Single dose, observed at 24 h and 96 h To evaluate the pharmacodynamics and pharmacokinetics of Anidulafungin in neutropenic mice. Results showed delayed peak concentrations in kidneys compared to serum, with a serum terminal half-life of 21.6 h. A single dose of ≥8 mg/kg resulted in a persistent decrease in kidney fungal burden over 96 h. PMC1635198
A129 mice SFTSV infection model Intraperitoneal injection 10 mg/kg Once daily for 14 days Evaluate the therapeutic effect of Anidulafungin on SFTSV-infected mice, results showed that Anidulafungin alleviates symptoms, reduces tissue lesions, and improves survival rates. PMC9585728
Hairless mice Candida albicans CNS infection model Intraperitoneal injection 10 mg/kg/day Once daily for 8 days To evaluate the efficacy of anidulafungin in treating Candida albicans CNS infection. Results showed that 10 mg/kg/day anidulafungin significantly reduced mortality and fungal burden in brain tissue, comparable to amphotericin B and superior to voriconazole. PMC2715626
BALB/c male mice Neutropenic mouse bloodstream infection model Intraperitoneal 5 mg/kg Once daily for 6 days To evaluate the in vivo efficacy of Anidulafungin against four Candida auris clades. Results showed that regardless of the isolate and clade, all echinocandin regimens significantly improved survival after 21 days (p=0.0041 to p<0.0001). Anidulafungin produced 1-4 log mean CFU/g decreases in the fungal kidney and heart burdens. PMC11433204

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01307930 Obesity|Mycoses PHASE4 COMPLETED 2025-11-12 University of Texas Southweste... More >>rn Medical Center, Dallas, Texas, 75390, United States Less <<
NCT00537329 Candidemia PHASE3 COMPLETED 2025-03-09 Pfizer Investigational Site, A... More >>hmedabad, Gujarat, 380 054, India|Pfizer Investigational Site, Bangalore, Karnataka, 560034, India|Pfizer Investigational Site, Mumbai, Maharashtra, 400 022, India|Pfizer Investigational Site, Ludhiana, Punjab, 141 001, India|Pfizer Investigational Site, Noida, Uttar Pradesh, 201301, India|Pfizer Investigational Site, Legaspi Village, Makati City, 1200, Philippines|Pfizer Investigational Site, Pan-Chiao, Taipei, 220, Taiwan|Pfizer Investigational Site, Taichung, 404, Taiwan|Pfizer Investigational Site, Tainan, 704, Taiwan|Pfizer Investigational Site, Taipei, 100, Taiwan|Pfizer Investigational Site, Pathumwan, Bangkok, 10330, Thailand|Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, 50200, Thailand|Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, 40002, Thailand Less <<
NCT01734525 Candidemia PHASE4 COMPLETED 2025-12-13 Federal University of Rio de J... More >>aneiro, Rio de Janeiro, RJ, 21941913, Brazil Less <<
NCT00734500 Invasive Fungal Infections PHASE1 COMPLETED 2025-06-10 Duke University, Durham, North... More >> Carolina, 27705, United States Less <<
NCT00058682 Candida|Candidiasis PHASE3 COMPLETED 2025-01-05 National Cancer Institute (NCI... More >>), Bethesda, Maryland, 20892, United States Less <<
NCT00892359 Acute Renal Failure|Infection PHASE2 UNKNOWN - Medical University of Vienna, ... More >>Vienna, 1090, Austria Less <<
NCT00056381 Neutropenia PHASE1|PHASE2 COMPLETED 2025-06-04 Versicor, King of Prussia, Pen... More >>nsylvania, 19406, United States Less <<
NCT01053884 Hematologic Malignancies PHASE2 TERMINATED 2025-09-11 Elisabethinen hospital, Linz, ... More >>Upper Austria, 4020, Austria Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.88mL

0.18mL

0.09mL

4.39mL

0.88mL

0.44mL

8.77mL

1.75mL

0.88mL

References

 

Historical Records

Categories